Peter Barrett - PerkinElmer Independent Director
| PKIDelisted Stock | USD 115.24 0.74 0.64% |
Director
Dr. Peter Barrett, Ph.D., is an Independent Director of PerkinElmer, Inc., Mr. Barrett joined Atlas Venture, an early stage life sciences VC fund, in 2002 and is a partner in the life sciences group. Previously, he was a cofounder, Executive Vice President and Chief Business Officer of Celera Genomics. Prior to that, Mr. Barrett held several senior management positions at The PerkinElmer Corporationrationration, most recently serving as Vice President, Corporationrationrate Planning and Business Development. He currently serves as the Chairman of Zafgen, Inc. and Synlogic, Inc., as well as a board member of several privately held companies, and during the past five years has served as a director of Akela Pharma, Inc., Alnylam Pharmaceuticals, Inc. and Momenta Pharmaceuticals, Inc. Mr. Barrett is also a senior fellow at the Harvard Business School. Mr. Barrett received his BS degree in chemistry from Lowell Technological Institute and his Doctoral degree in analytical chemistry from Northeastern University since 2012.
| Age | 68 |
| Tenure | 12 years |
| Phone | 781 663 6900 |
| Web | https://www.perkinelmer.com |
PerkinElmer Management Efficiency
The company has Return on Asset of 0.0369 % which means that on every $100 spent on assets, it made $0.0369 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0706 %, implying that it generated $0.0706 on every 100 dollars invested. PerkinElmer's management efficiency ratios could be used to measure how well PerkinElmer manages its routine affairs as well as how well it operates its assets and liabilities.The company has 3.92 B in debt with debt to equity (D/E) ratio of 0.65, which is OK given its current industry classification. PerkinElmer has a current ratio of 1.98, which is typical for the industry and considered as normal. Debt can assist PerkinElmer until it has trouble settling it off, either with new capital or with free cash flow. So, PerkinElmer's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PerkinElmer sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PerkinElmer to invest in growth at high rates of return. When we think about PerkinElmer's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jeffrey Davis | Laboratory of | 57 | |
| Joshua Bekenstein | Waters | 56 | |
| Michael Berendt | Waters | 71 | |
| Stuart Essig | IDEXX Laboratories | 56 | |
| Judy Lewent | Thermo Fisher Scientific | 71 | |
| Robert Epstein | Illumina | 62 | |
| Martiny Harris | Thermo Fisher Scientific | 59 | |
| Daniel Bradbury | Illumina | 56 | |
| Donald Ehrlich | Danaher | 80 | |
| George Milne | Mettler Toledo International | 71 | |
| Carol Burt | IQVIA Holdings | 62 | |
| Wah Chu | Mettler Toledo International | 62 | |
| Connie Harvey | Mettler Toledo International | 52 | |
| Karin Eastham | Illumina | 67 | |
| William End | IDEXX Laboratories | 68 | |
| Caroline Dorsa | Illumina | 58 | |
| Raymond Stevens | Danaher | 57 | |
| Michael Evanisko | IQVIA Holdings | 68 | |
| Martin Harris | Thermo Fisher Scientific | 61 | |
| Eugene McCague | ICON PLC | N/A | |
| Heidi Fields | Agilent Technologies | 60 | |
Management Performance
| Return On Equity | 0.0706 | |||
| Return On Asset | 0.0369 |
PerkinElmer Leadership Team
Elected by the shareholders, the PerkinElmer's board of directors comprises two types of representatives: PerkinElmer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PerkinElmer. The board's role is to monitor PerkinElmer's management team and ensure that shareholders' interests are well served. PerkinElmer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PerkinElmer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michel Vounatsos, Independent Director | ||
| Sylvie Gregoire, Independent Director | ||
| Pascale Witz, Independent Director | ||
| Miriame Victor, Chief Commercial Officer, Senior Vice President | ||
| Jonathan DiVincenzo, Sr. VP and President of Environmental Health | ||
| Patrick Sullivan, Independent Director | ||
| Stephen Willoughby, VP ESG | ||
| Tajinder Vohra, Senior Vice President Global Operations | ||
| Prahlad Singh, Senior Vice President and President - Diagnostics | ||
| Robert Friel, Chairman, CEO and President and Member of Fin. Committee | ||
| Vicki Sato, Independent Director | ||
| Maxwell Krakowiak, VP CFO | ||
| Daniel Tereau, Senior Vice President Strategy and Business Development | ||
| Alexandros Michas, Independent Non-Executive Chairman of the Board | ||
| Nicholas Lopardo, Lead Independent Director | ||
| Franklin Witney, Director | ||
| Joel Goldberg, Senior Vice President - Administration, General Counsel, Secretary | ||
| James Corbett, Sr. VP and President of Human Health | ||
| Kenton Sicchitano, Independent Director | ||
| Samuel Chapin, Independent Director | ||
| James Mock, Chief Financial Officer, Senior Vice President | ||
| Andrew Okun, Chief Accounting Officer, Vice President, Treasurer | ||
| Peter Barrett, Independent Director | ||
| Deborah Butters, Chief Human Resource Officer, Senior Vice President | ||
| Frank Witney, Independent Director | ||
| John Letcher, Senior Vice President - Human Resources | ||
| Alexis Michas, Independent Non-Executive Chairman of the Board | ||
| Jon DiVincenzo, Senior Vice President and Presidentident - Environmental Health | ||
| Masoud Toloue, VP Diagnostics | ||
| Frank Wilson, CFO and Sr. VP |
PerkinElmer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PerkinElmer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0706 | |||
| Return On Asset | 0.0369 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 22.3 B | |||
| Shares Outstanding | 126.41 M | |||
| Shares Owned By Insiders | 0.26 % | |||
| Shares Owned By Institutions | 86.25 % | |||
| Number Of Shares Shorted | 3.53 M | |||
| Price To Earning | 21.07 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PerkinElmer using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in PerkinElmer Stock
If you are still planning to invest in PerkinElmer check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PerkinElmer's history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |